Summary
Datamonitor's UCB Group - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
UCB is a global biopharmaceutical company. The company focuses on severe diseases in the fields of central nervous system (including epilepsy), inflammation (including allergy), and oncology. It has more than 140 subsidiaries in Europe, North and South America, and Asia. The company is headquartered in Brussels, Belgium and employs more than 12,100 people. The company recorded revenues of E3,626 million (approximately $5,340.6 million) during the fiscal year ended December 2007, an increase of 42.1% over 2006. The operating profit of the company was E344 million (approximately $506.7 million) during fiscal year 2007, a decrease of 39.8% over 2006. The net profit was E161 million (approximately $237.1 million) in fiscal year 2007, a decrease of 56.1% over 2006.
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available.
|
